Comparison of Intravitreal Bevacizumab and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity

Roohipoor, Ramak; Karkhaneh, Reza; Riazi‐Esfahani, Mohammad; Farahani, Afsar Dastjani; Khodabandeh, Ali; Adib, Nazanin Ebrahimi; Imani, Mehdi; Jafari, Hassan; Riazi-Esfahani, Hamid; Hosseinpour, Jamaleddin; Zarei, Mohammad; Ghasemi, Hassan; Mirghorbani, Masoud; Yaseri, Mehdi; Davoudi, Samaneh; Modjtahedi, Bobeck S.

doi:10.1016/j.oret.2018.01.017

Cited by 32 publications

(30 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the report, the rebound elevation persisted for a long time and caused delayed bilateral retinal neovascularization and hemorrhage. According to these results, rebound elevation after intravitreal anti‐VEGF injection might be a reason for delayed recurrence of ROP after intravitreal anti‐VEGF injection, which is sometimes observed in clinical practice 2,29 …”

Section: Discussionmentioning

confidence: 88%

The systemic antiangiogenic effect of intravitreal aflibercept injection in a mouse model of retinopathy of prematurity

et al. 2021

View full text Add to dashboard Cite

Retinopathy of prematurity (ROP) is a leading cause of childhood blindness and intravitreal anti‐vascular endothelial growth factor (VEGF) injection is becoming a first‐line choice for treatment of ROP. However, there is a major concern that intravitreally injected anti‐VEGF agents could escape from the eye into the systemic circulation and impair systemic development. Moreover, escaped anti‐VEGF agents could have an effect on the retina of the fellow eye. In this study, we investigated the hematogenous effect of a single intravitreal anti‐VEGF injection in a mouse model of ROP. Here, we showed that single intravitreal aflibercept injection to one eye can affect body weight gain, the fellow eye, and renal vessels, although no apparent effect was observed in brain vessels. Furthermore, this hematogenous effect was dose‐dependent. Our results provide very important insights into the clinical use of anti‐VEGF agents for ROP treatment.

show abstract

Section: Discussionmentioning

confidence: 88%

The systemic antiangiogenic effect of intravitreal aflibercept injection in a mouse model of retinopathy of prematurity

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Bevacizumab provides faster regression of ROP than laser treatment and permits peripheral retinal vascularization with the benefit of being less destructive than laser treatment [14,15]. It has been shown that more favorable refractive outcome can be achieved by anti-VEGF agents [2,14,15].…”

Section: Discussionmentioning

confidence: 99%

“…Retinopathy of prematurity (ROP) still is one of the leading causes of permanent visual loss worldwide [1]. Developing in premature children healthcare, and lack of proper ROP screening programs have resulted in high disease prevalence in the developing countries [2].…”

Section: Introductionmentioning

confidence: 99%

“…These treatments destroy the peripheral avascular retina to regress the neovascularisation by decreasing the production of VEGF [5] Riazi-esfahani et al Int J Retin Vitr (2021) 7:60 Some investigations have shown encouraging treatment outcomes after intravitreal bevacizumab (IVB) as a first-line treatment especially for Zone I ROP and aggressive posterior ROP (APROP) [6,7]. In contrast to ablative therapies, anti-VEGF therapy is associated with a lower rate of high myopia and peripheral visual field loss, although it needs a longer intense follow-up schedule [2,8].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background To evaluate the outcome of intravitreal bevacizumab (IVB) and aflibercept (IVA) injection for patients with retinopathy of prematurity (ROP). Methods In this single-center retrospective cohort, the recorded medical data of the infants who had been undergone intravitreal injection with either bevacizumab or aflibercept for type 1 ROP were reviewed. The infants were allocated into two groups. IVB group included patients who were treated with bevacizumab as initial treatment and the IVA group included patients who were treated with aflibercept as initial treatment. The rate and time of complete regression, as well as the recurrence rates, were compared between the groups. Results A total of 889 eyes of 453 infants were enrolled in the study. There were 865 eyes of 441 infants in the IVB group and 24 eyes of 12 infants in the IVA group. Follow-up time was 289 ± 257 days in the IVB group and 143 ± 25 days in the IVA group (p < 0.001). The difference in the ROP zone was not statistically significant between the 2 treatment groups (p = 0.328). All eyes in the IVA group showed initial regression of ROP after the intravitreal injections. These regressions were achieved in 830 (96.0%) eyes that were injected with IVB (p = 0.023). The median observed regression time was 10 days and 16 days in eyes treated with bevacizumab and aflibercept respectively. Recurrence was noted in 3.9% of eyes (34/865) in the IVB group and 58.3% of eyes (14/24) in the IVA group (p < 0.001). Conclusion While the regression rate in the IVA group was significantly higher than in the IVB group, the recurrence rate was significantly more in the IVA group, which may be attributed to differences in the pharmacokinetics of these drugs in the vitreous body.

show abstract

“…So far, most studies on IVB treatment reported cross-sectional refractive error outcome at approximately 1 year of age to 3 years of age [9, 10, 12–15, 18–27]. Only one study reported longitudinal data up to 5 years of age [16].…”

Section: Introductionmentioning

confidence: 99%

Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review

2019

View full text Add to dashboard Cite

ObjectiveTo investigate refractive error development in preterm children with severe retinopathy of prematurity (ROP) treated with anti-vascular endothelial growth factor (anti-VEGF) agents and laser photocoagulation.MethodsSelection criteria were comparative studies that compared the refractive errors in children, birthweights ≤1500 grams and gestational ages ≤30 weeks, and treatments for Type I ROP with intravitreal bevacizumab (IVB) versus laser photocoagulation. Studies were identified using PubMed, Google Scholar, and published reviews. Meta-analyses were performed on the post-treatment outcomes of spherical equivalent (SEQ), cylindrical power, and prevalence of high myopia. Longitudinal development of refractive error in IVB, or in laser-treated children, or in normal full-term children was visually summarized.ResultsTwo randomized controlled trials and 5 non-randomized studies, including a total of 272 eyes treated by IVB and 247 eyes treated by laser, were included in this study. Compared with laser-treated children, IVB-treated children have less myopic refractive error (P<0.001), lower prevalence of high myopia (P<0.05), and less astigmatism (P = 0.02).ConclusionsTreatment with IVB is associated with less myopia and astigmatism than laser treatment for infants with severe ROP. Given the complexity of ROP and the variability of dosing, our review supports close monitoring of refractive error outcomes in children treated with IVB.

show abstract

Comparison of Intravitreal Bevacizumab and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity

Cited by 32 publications

References 24 publications

The systemic antiangiogenic effect of intravitreal aflibercept injection in a mouse model of retinopathy of prematurity

The systemic antiangiogenic effect of intravitreal aflibercept injection in a mouse model of retinopathy of prematurity

Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity

Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review

Contact Info

Product

Resources

About